Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 15/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 15/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825360 | 0.92 | CSNK1D (0.59) | TGFBR1CSNK1DCSNK1E | |
| SCHEMBL15830665 | 0.88 | TGFBR1 (0.63) | TGFBR1CSNK1DCSNK1E | |
| SCHEMBL15823237 | 0.82 | CSNK1D (0.61) | TGFBR1CSNK1DCSNK1E | |
| SCHEMBL18041512 | 0.82 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL1639802 | 0.81 | MAPK14 (0.66) | TGFBR1CSNK1DCSNK1E | |
| SCHEMBL15826565 | 0.80 | CSNK1D (0.68) | CSNK1DCSNK1E | |
| SCHEMBL15830598 | 0.79 | CSNK1D (0.50) | TGFBR1CSNK1DCSNK1E | |
| SCHEMBL18042092 | 0.79 | TGFBR1 (0.84) | TGFBR1 | |
| SCHEMBL17291524 | 0.79 | CSNK1D (0.65) | CSNK1DCSNK1E | |
| SCHEMBL15830663 | 0.79 | CSNK1D (0.64) | TGFBR1CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| WO-2014100533-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | TGFBR1 3920/4885CSNK1D 5/4885CSNK1E 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.